RefluxStop® Shines at Foregut Conference with 5-Year Outcomes
VADUZ, Liechtenstein – Implantica AG (publ), a progressive medtech company known for its state-of-the-art technology, recently captured attention at the Japan Foregut Conference. The event, coordinated by Dr. Yasuhiro Fujiwara from Osaka Municipal University, assembled around 120 influential surgeons and gastroenterology specialists who are pioneers in their field and dedicated to advancing treatments for foregut diseases.
This conference served as a vital stage for the presentation of significant, long-term clinical findings regarding the RefluxStop® device.
Key Clinical Evidence Presented
The conference featured pivotal presentations that showcased the 5-year outcomes of the RefluxStop® device, underscoring its long-term efficacy in addressing gastroesophageal reflux disease (GERD). Notably, a comprehensive study revealed that an impressive 97.9% of patients transitioned away from daily proton pump inhibitor (PPI) medication after five years.
Safety Cohort Findings
Dr. Moustafa Elshafei, a recognized authority in this arena, delivered findings from a robust cohort of 602 patients, emphasizing the favorable safety profile of the RefluxStop® device. This information illustrates that the device effectively sidesteps common complications associated with traditional anti-reflux surgeries, such as swallowing difficulties and gas-bloating.
Growing Demand for GERD Solutions
Professor Yano from Jikei University in Tokyo addressed the conference, highlighting the rising incidence of GERD in Japan. He emphasized the necessity for a device like RefluxStop®, which targets the root cause of the condition—a failure in the body’s natural anti-reflux barrier.
Dr. Peter Forsell, CEO and founder of Implantica, expressed his appreciation for the warm reception of the technology by the Japanese medical community. During his remarks, he pointed out that while treatment preferences for GERD in Japan have differed from those in the West, the condition has seen a sharp rise since the 1990s. Currently, it affects an estimated 17.9% of Japanese adults. He noted, "The increasing awareness of effective, side-effect-free options like RefluxStop® reflects a global demand for revolutionary GERD solutions in Japan."
About Implantica and RefluxStop®
Implantica is a medtech group focused on the introduction of advanced medical technologies. The RefluxStop® product stands out as a CE-marked implant designed for preventing gastroesophageal reflux, with its innovative approach expected to redefine anti-reflux treatments—backed by positive clinical trial outcomes. The company not only emphasizes eHealth innovations inside the body but also possesses a diverse and patented pipeline fueled by two primary technological platforms: an advanced eHealth monitoring system and a wireless energy transfer technology enabling remote control of implants.
The RefluxStop® solution intrinsically treats the underlying causes of acid reflux without constraining the food passage. Unlike traditional surgical options that can induce various postoperative discomforts, RefluxStop® restores and maintains the natural position of the lower esophageal sphincter, optimizing physiological function and enhancing patient outcomes.
Future Directions
Moving forward, Implantica continues to prioritize collaboration within the global medical community, seeking to elevate the standard of care for GERD and advance surgical techniques surrounding this prevalent condition. The company's commitment to innovation promises exciting developments in the field of medtech, particularly in relation to minimally invasive procedures.
Frequently Asked Questions
What is RefluxStop®?
RefluxStop® is an innovative device developed by Implantica that prevents gastroesophageal reflux disease with minimal side effects.
Why was the Japan Foregut Conference significant?
The conference gathered top surgeons to discuss groundbreaking treatments, showcasing relevant data on RefluxStop® and its positive outcomes in GERD management.
What were the 5-year outcomes of RefluxStop®?
At five years, 97.9% of patients no longer required daily PPI medication, demonstrating the device's effectiveness in long-term GERD treatment.
How does RefluxStop® differ from traditional GERD treatments?
Unlike standard surgeries that compress the esophagus, RefluxStop® restores the lower esophageal sphincter to its natural position without added pressure, reducing common surgery-related side effects.
What future plans does Implantica have?
Implantica aims to expand its innovative technologies and continuously enhance treatment options for gastroesophageal reflux, meeting global healthcare needs.
